Grifols, S.A. (NASDAQ:GRFS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Grifols, S.A. (NASDAQ:GRFS) have been assigned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $10.30.

Several equities analysts have commented on GRFS shares. JPMorgan Chase & Co. increased their target price on shares of Grifols from $7.60 to $10.30 and gave the stock a “neutral” rating in a research report on Tuesday, June 17th. Weiss Ratings reissued a “hold (c)” rating on shares of Grifols in a research report on Saturday, September 27th. Zacks Research raised shares of Grifols to a “hold” rating in a research report on Friday, August 8th. Wall Street Zen raised shares of Grifols from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 7th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Grifols in a research report on Tuesday, August 5th.

Institutional Investors Weigh In On Grifols

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Grifols by 2.4% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 47,192 shares of the biotechnology company’s stock valued at $427,000 after acquiring an additional 1,114 shares during the last quarter. Oppenheimer Asset Management Inc. raised its stake in shares of Grifols by 4.9% in the second quarter. Oppenheimer Asset Management Inc. now owns 62,991 shares of the biotechnology company’s stock valued at $569,000 after acquiring an additional 2,928 shares during the last quarter. Sequoia Financial Advisors LLC raised its stake in shares of Grifols by 14.9% in the first quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 3,399 shares during the last quarter. Versant Capital Management Inc bought a new position in shares of Grifols in the first quarter valued at approximately $28,000. Finally, Cerity Partners LLC raised its stake in shares of Grifols by 22.8% in the first quarter. Cerity Partners LLC now owns 22,254 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 4,129 shares during the last quarter.

Grifols Trading Down 0.7%

Grifols stock opened at $9.95 on Friday. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.64 and a quick ratio of 0.95. The company has a market capitalization of $6.84 billion, a price-to-earnings ratio of 8.50, a PEG ratio of 0.34 and a beta of 0.69. Grifols has a one year low of $6.19 and a one year high of $11.14. The company’s fifty day moving average price is $10.13 and its two-hundred day moving average price is $8.82.

Grifols Announces Dividend

The firm also recently declared a special dividend, which was paid on Wednesday, August 20th. Stockholders of record on Tuesday, August 12th were given a $0.1404 dividend. The ex-dividend date of this dividend was Tuesday, August 12th. Grifols’s dividend payout ratio (DPR) is currently 11.97%.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.